Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of durvalumab in HIV-1-positive patients with advanced solid tumors
2016-004524-38Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Jan 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in Nonhematologic neoplasms, sponsored by Fundación GECP. Primary endpoint: Feasibility of durvalumab monotherapy. Started Jan 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2016-004524-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004524-38.